BridgeBio Pharma, Inc. (BBIO)
BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews
BridgeBio Pharma maintains a "Strong Buy" rating, driven by robust revenue growth and multiple late-stage pipeline catalysts. The company delivered Q2 2026 net revenues of $243.7M, up from the prior year's $110.6M, outperforming despite competition. Three NDA submissions—BBP-418, oral infigratinib, and encaleret—are under Priority Review, with PDUFA dates spanning late 2026 to mid-2027.
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BridgeBio Pharma: Attruby Peak Sales Set To Rise
BridgeBio pharma has delivered multiple clinical and commercial successes, yet shares have repeatedly sold off after positive catalysts. Infigratinib's dwarfism trial outperformed the market leader, and Attruby continues to beat sales estimates, with management now guiding higher peak sales. Recent competitor setbacks and new data on Attruby's kidney benefits and hospital day reduction further strengthen BBIO's commercial outlook.
BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock?
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.
BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months
BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance, and expectations for three product launches by mid-2027. Attruby's U.S. net sales surged 311% Y/Y, with ex-U.S. Beyonttra royalties up 62% sequentially as they continue to gain TTR stabilizer market share. BBIO's $1B preferred equity raise addresses balance sheet concerns, supporting accelerated commercial and pipeline investment.
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
